
    
      This study is planned to be carried out in Zhejiang and Jiangsu province regional
      multi-center. 44 cases are preliminarily expected to be included. The study started in
      January 2019 and ended in December 2019. It is expected that the trial will end in December
      2020.

      In the absence of such situations as withdrawal of informed consent, intolerance of drug
      toxicity and side effects, or inappropriateness for further trials, each participant's
      expected time for research and treatment will continue until radiographically confirmed tumor
      progression occurs.
    
  